← Companies|BioNTech
BN

BioNTech

BNTX·NASDAQMainz DEFounded 20086,200 employees
Large CapbiotechPublicOncologyInfectious DiseaseImmunology
Platform: mRNA & IO
Market Cap
$28B
All Drugs
7
Clinical Trials
11
Failed / Terminated
3
FDA Approved
0
Stock Price & Catalysts (BNTX)
Loading BNTX stock data...
Drug Pipeline (7 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
BNT-8090BNT-8090Phase 21Gene EditingAuroraAPD-L1iOvarian CaParkinson's
NirabrutinibBNT-9712Phase 2/31ASOCDK2PD-1iCF
BemanesiranBNT-1610Phase 33mRNAPLK4HPK1iACCMDD
BNT-5232BNT-5232NDA/BLA1mRNATIGITPARPiETEpilepsy
ZenotinibBNT-2601Phase 12VaccineCGRPAnti-AβMCLGIST
DarafutibatinibBNT-9021Preclinical1PeptidePRMT5CFTRmodOCD
CapiglumideBNT-1313Preclinical2VaccineCGRPMDM2iAsthma
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (11)
2025-04-17
Bemanesiran Ph3 Readout
MDD
Past
2025-10-12
Capiglumide Interim
Asthma
Past
2026-08-14
Bemanesiran Ph3 Readout
MDD
Ph3 Readout
2027-02-25
Nirabrutinib Ph3 Readout
CF
Ph3 Readout
2027-08-27
Zenotinib Interim
MCL
Interim
2027-10-21
BNT-8090 Ph2 Data
Parkinson's
Ph2 Data
2028-01-20
Bemanesiran Ph3 Readout
MDD
Ph3 Readout
2028-08-03
Capiglumide Interim
Asthma
Interim
2028-10-12
BNT-5232 Ph3 Readout
Epilepsy
Ph3 Readout
2030-01-19
Zenotinib Interim
GIST
Interim
2031-09-23
Darafutibatinib Interim
OCD
Interim